PGPeter Gerner

Peter Gerner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter Gerner has a total of 287 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Essential Clinical Anesthesia

    by Scott Segal, Charles A. Vacanti, Pankaj K. Sikka, Richard D. Urman, Mark Dershwitz, B. Scott Segal, Linda S. Aglio, Paul D. Allen, Angela M. Bader, Sascha S. Beutler, et al.

    The clinical practice of anesthesia has undergone many advances in the past few years, making this the perfect time for a new state-of-the-art anesthesia textbook for practitioners and trainees. The goal of this book is to provide a modern, clinically focused textbook giving rapid access to comprehensive, succinct knowledge from experts in the field. All clinical topics of relevance to anesthesiology are organized into 29 sections consisting of more than 180 chapters. The print version contains 166 chapters that cover all of the essential clinical topics, while an additional 17 chapters on subjects of interest to the more advanced practitioner can be freely accessed at www.cambridge.org/vacanti. Newer techniques such as ultrasound nerve blocks, robotic surgery and transesophageal echocardiography are included, and numerous illustrations and tables assist the reader in rapidly assimilating key information. This authoritative text is edited by distinguished Harvard Medical School faculty, with contributors from many of the leading academic anesthesiology departments in the United States and an introduction from Dr S. R. Mallampati. This book is your essential companion when preparing for board review and recertification exams and in your daily clinical practice.


  • “Above All, Do No Harm”

    by Peter Gerner

    LOCAL anesthetics block voltage-gated sodium channels, thereby preventing generation of action potentials and their propagation along the nerve. However, complete sensory blockade is generally accomplished only with simultaneous sympathetic and motor blockade, thereby often leading to unwanted adverse side effects. To date, no agent or method translatable into current clinical practice has been shown to elicit usable, predominantly sensory nerve blocks. In this issue of Anesthesiology, Brummett et al. 1 report the approach of combining ropivacaine with an α2agonist (dexmedetomidine), thereby dose-dependently increasing the duration of sensory blockade over motor blockade in a rat sciatic nerve block model. Logically, the questions of whether and how to progress to clinical studies arise.


  • An Absorbable Local Anesthetic Matrix Provides Several Days of Functional Sciatic Nerve Blockade

    by Chi-Fei Wang, Alimorad G. Djalali, Ankur Gandhi, David Knaack, Umberto De Girolami, Gary Strichartz, Peter Gerner

    Injection. We report on an implantable, controlled-release drug delivery system intended for use in bone and consisting of a Food and Drug Administration-approved matrix containing lidocaine that is capable of local delivery for several days. METHODS: Xybrex™, an absorbable, controlled-release delivery system containing 16% (w/w) lidocaine, was implanted next to the sciatic nerve of male rats (300–350 gm), at lidocaine doses of 5.3, 10.6, 16, and 32 mg lidocaine per rat. For comparison, a lidocaine HCl solution (0.2 mL, 2% = 4 mg) was injected in close proximity to the sciatic nerve. Rats were assessed behaviorally for analgesia by a forceps pinch of the lateral digits, and for motor block by quantifying the extensor postural thrust. Potential neurotoxicity of sciatic nerves was evaluated histologically at 24 h, 4 days, and 4 wk after implantation. The kinetics of lidocaine’s release from the matrix was measured in vitro by ultraviolet detection of lidocaine in samples collected at 2.5, 6.5, 20, and 24.25 h. RESULTS: Xybrex at the highest doses (300 and 600 mg/kg, containing 16 and 32 mg of lidocaine free base, respectively) provided complete analgesia to an intense pinch for 7.0 ± 2.0 h, 6.9 ± 1.7 h and partial analgesia for 60.0 ± 5.4 h, 58.8 ± 4.2 h, respectively, compared to 0.61 ± 0.03 h of complete analgesia and 0.96 ± 0.03 h of partial analgesia by sciatic block from the 2% lidocaine solution (containing 4 mg lidocaine). These same high doses of Xybrex produced complete motor block for 17.0 ± 3.3 h, 17.6 ± 3.3 h with full recovery in 352.0 ± 55.7 h (14.7 ± 2.3 days), 579.0 ± 36.1 h (24.1 ± 1.5 days) respectively. Data are reported as mean ± se. P < 0.001 for all Xybrex groups compared to the 2% lidocaine group. Minor local tissue inflammation/pathology, primarily in the connective tissue and muscle 0.1 mm adjacent to the nerve, was observed equally in animals treated with Xybrex and 2% lidocaine solution. There were no behavioral signs of systemic toxicity. The in vitro release followed exponential kinetics and its comparison to the time-course of functional nociceptive deficit implied that the duration of nociception represented the local, immediate interaction of lidocaine between the nerve and the matrix and not a cumulative effect of previously released drug. CONCLUSIONS: Xybrex is an absorbable, controlled-release drug delivery system that provides several days of analgesia for rat peripheral nerves without apparent significant local neurotoxicity or systemic toxicity....


  • Open Access

    Capsaicin Combined with Local Anesthetics Preferentially Prolongs Sensory/Nociceptive Block in Rat Sciatic Nerve

    by Peter Gerner, Alexander M. Binshtok, Chi-Fei Wang, Nathanael D. Hevelone, Bruce P. Bean, Clifford J. Woolf, Ging Kuo Wang

    Background: Transient receptor potential vanilloid 1 channels integrate nociceptive stimuli and are predominantly expressed by unmyelinated C-fiber nociceptors, but not low-threshold mechanoreceptive sensory or motor fibers. A recent report showed that the transient receptor potential vanilloid 1 channel agonist capsaicin allows a hydrophilic quaternary ammonium derivative of lidocaine, QX-314, to selectively block C fibers without motor block. The authors tested whether a similar differential block would be produced using amphipathic N-methyl amitriptyline, amitriptyline, bupivacaine, or lidocaine, either alone or together with 0.05% capsaicin, in a rat sciatic nerve block model. Methods: Rats (n = 8/group) were anesthetized with sevoflurane, and 0.2 ml of drug was injected either alone or with capsaicin (simultaneously or 10 min later) next to the sciatic nerve in the sciatic notch. Motor function was assessed by the extensor postural thrust. Nociception was evaluated by the nocifensive withdrawal reflex and vocalization evoked by pinch of a skin fold over the lateral metatarsus (cutaneous pain) with a serrated forceps. Results: N-Methyl amitriptyline, amitriptyline, bupivacaine, or lidocaine, followed by injection of capsaicin 10 min later, each elicited a predominantly nociceptive-specific blockade. In comparison, simultaneous application of each local anesthetic with capsaicin did not elicit a clinically significant differential block, with the exception of N-methyl amitriptyline. Conclusions: Both tertiary amine local anesthetics and their quaternary ammonium derivatives can elicit a predominantly sensory/nociceptor selective block when followed by injection of capsaicin. The combined application of transient receptor potential vanilloid 1 channel agonists and various local anesthetics or their quaternary ammonium derivatives is an appealing strategy to achieve a long-lasting differential block in regional analgesia.


  • Impact of Analgesia on Bone Fracture Healing

    by Peter Gerner, J Patrick O’cOnnor

    BONE fractures are painful and, in general, temporarily disabling injuries that occur after trauma or as an end result of various pathologic conditions, such as osteoporosis or bone invading cancer (pathologic fracture). It is common practice for acute pain services to be heavily involved in the treatment of orthopedic patients, and although it is usually understood that fractures are very painful, few studies have directly attempted to measure or define the nature of the pain after a fracture. In addition, controversy exists regarding the effects of analgesics, including opioids and nonsteroidal antiinflammatory drugs, on skeletal tissue healing. In this issue of Anesthesiology, reports from Freeman et al. 1 and Minville et al. 2 show that commonly used fracture healing models also can be used to assess pain quantitatively and therefore to assess analgesic efficacy. Because bone is a highly innervated tissue, these models also can be applied to define the mechanism of pain transmission after fracture. Furthermore, and of even greater clinical importance, these fracture pain models lend themselves to studying the effects of pharmacologic interventions on bone healing.


  • Magnesium Sulfate Diminishes the Effects of Amide Local Anesthetics in Rat Sciatic-Nerve Block

    by Y Hung, C Chen, P Lirk, C Wang, J Cheng, G Wang, P Gerner

    Magnesium sulfate (MgSO(4)) is well known as an antagonist of N-methyl-d-aspartate receptors and was used for intrathecal analgesia a century ago. However, the effects of MgSO(4) combined with local anesthetics (LAs) on peripheral nerves are unclear. We tested the hypothesis that MgSO(4) could be used as an adjuvant to prolong and intensify conduction block by amide-type LAs in a rat sciatic-nerve block model. Further, the mechanism of possible synergy between LAs and MgSO(4) was investigated in whole-cell mode patch-clamp experiments. Sciatic nerves were exposed to 2%/73.9 mM lidocaine, 0.25%/7.7 mM bupivacaine, and 0.5%/15.4 mM ropivacaine, with or without addition of 1.25%, 2.5%, or 5% MgSO(4)/50.7 mM, and nerve block characteristics were assessed. To elucidate the LA-MgSO(4) interaction, voltage-dependent inactivation curves were determined in cultured rat GH(3) cells that expressed neuronal Na(+) channels. Unexpectedly, the addition of MgSO(4) overall significantly shortened the duration of block by lidocaine, bupivacaine, and ropivacaine. The steady-state inactivation of Na(+) channels in the presence of 300 muM lidocaine was almost unchanged by the addition of 10 mM MgSO(4), indicating that MgSO(4) does not affect the potency of lidocaine toward the inactivated Na(+) channel. MgSO(4) coadministered with amide-type LAs shortened the duration of sciatic-nerve block in rats. Therefore, it does not seem to be useful as an adjuvant for peripheral-nerve block. The mechanism of this observed antagonism is unclear but appears to be independent of the action of LAs and MgSO(4) at the LA receptor within the Na(+) channel.


  • Phase 1A Safety Assessment of Intravenous Amitriptyline

    by Peter Fridrich, Hans Peter Colvin, Anthony Zizza, Ajay D. Wasan, Jean Lukanich, Philipp Lirk, Alois Saria, Gerald Zernig, Thomas Hamp, Peter Gerner


  • Doxepin by Topical Application and Intrathecal Route in Rats

    by Peter Gerner, Venkatesh Srinivasa, Anthony M. Zizza, Zhi-Ye Zhuang, ShiHua Luo, David Zurakowski, Sunil Eappen, GingKuo Wang

    The tricyclic antidepressant, doxepin, has been reported to be a potent local anesthetic in rat sciatic nerve blockade. We hypothesized that topical doxepin has significantly longer antinociception compared with control and intrathecally compared with bupivacaine. Solutions of 0.3 mL of doxepin at 50, 75, and 100 mM and control (only the vehicle solution) were applied as a patch to the shaved dorsal skin of rats. After a 2-h contact interval, the patch was removed, and the rats were tested by three sets of six pinpricks. Inhibition of withdrawal to pain and cutaneous trunci muscle reflex were graded. In the second investigation, 60 μL of doxepin at 10, 20, and 50 mM was injected through intrathecal catheters implanted in the lumbar region of rats, which were evaluated for motor function, proprioception, and nociception. Topical doxepin at concentrations of 75 mM and 100 mM was significantly more effective than control (P < 0.05). Complete recovery for the 100-mM concentration occurred at 60 h, although two of five rats demonstrated erythema and scarring. Intrathecally, 20 mM of doxepin was not significantly different for motor and proprioceptive function from 23 mM (0.75%) bupivacaine; however, neurotoxicity (defined as persistent neurological deficit) commenced at 50 mM.


  • Differential Block of N-Propyl Derivatives of Amitriptyline and Doxepin for Sciatic Nerve Block in Rats

    by Peter Gerner, Shi Hua Luo, Zhi-Ye Zhuang, Alimorad G. Djalali, Anthony M. Zizza, Robert R. Myers, Ging Kuo Wang

    The propyl group of ropivacaine (N-propyl-2′,6′-pipecoloxylidide hydrochloride) could be responsible for conferring some sensory selectivity to this drug. Thus, adding a propyl group to experimental local anesthetics (LAs) (e.g., the tricyclic antidepressants amitriptyline and doxepin) to increase sensory selectivity may be useful. We, therefore, synthesized N-propyl amitriptyline and N-propyl doxepin and investigated a potential predominance of sensory/nociceptive block over motor block (differential block) in a rat sciatic nerve block model. In addition, tetrodotoxin (TTX), a naturally occuring Na+ channel blocker, was coinjected to investigate whether it increased block duration.